Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy
Abstract The combination of chemotherapy and immune checkpoint blockade therapy shows great potential in tumor treatment, but their integration remains a great challenge. Herein, hypoxia-responsive prodrugs integrating paclitaxel (PTX) and bromodomain-containing protein 4 inhibitor JQ1 were designed...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2025-12-01
|
| Серія: | Journal of Nanobiotechnology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12951-025-03894-x |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|